2. Search Result
Search Result
Results for "

DOTA chelator

" in MedChemExpress (MCE) Product Catalog:

51

Inhibitors & Agonists

1

Fluorescent Dyes

26

Biochemical Assay Reagents

6

Peptides

1

Inhibitory Antibodies

3

Click Chemistry

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117410
    Vipivotide tetraxetan
    15+ Cited Publications

    PSMA-617

    		 Drug-Linker Conjugates for ADC Cancer
    Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a Ki of 0.37 nM. Vipivotide tetraxetan (PSMA-617) is designed consisting of three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA able to complex both 68Ga or 177Lu, and a linker connecting these two entities. Glutamate-urea-Lysine is the selective pharmacophore to bind to prostate specific membrane antigen.
    Vipivotide tetraxetan
  • HY-P99239
    Rosopatamab

    HUJ-591; TLX591

    		 PSMA Radionuclide-Drug Conjugates (RDCs) Cancer
    Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
    Rosopatamab
  • HY-W087187
    DOTAGA-anhydride

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Infection Cancer
    DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .
    DOTAGA-anhydride
  • HY-131326
    DOTA-tris(tBu)ester NHS ester

    		Biochemical Assay Reagents Cancer
    DOTA-tris(tBu)ester NHS ester is a bifunctional precursor to a DOTA-based chelating agent. DOTA-tris(tBu)ester NHS ester can be used to label primary amines (R-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules, and upon deprotection forms stable complexes with metal ions for applications in molecular imaging .
    DOTA-tris(tBu)ester NHS ester
  • HY-100138
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)

    		Radionuclide-Drug Conjugates (RDCs) ADC Linker Cancer
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) is a metal chelator precursor containing a DOTA macrocyclic structure. DOTA can form highly stable complexes with metal ions (such as 68Ga, 177Lu) through four nitrogen atoms and four carboxylic acid groups to mediate targeted delivery of radionuclides. The tert-butyl ester group (tBu ester) of 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) also protects the carboxylic acid group during synthesis, and forms a free carboxyl group after deprotection reaction for coupling with targeting molecules (such as antibodies, peptides). 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) may be combined with tumor pre-targeting systems through bioorthogonal reactions (such as reverse electron demand Diels-Alder reaction) to study radioactive imaging or therapy of tumor tissues, and is mainly used in tumor pre-targeting research in the field of nuclear medicine .
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)
  • HY-159181
    p-NCS-Bz-DOTA-GA

    		Biochemical Assay Reagents Others
    p-NCS-Bz-DOTA-GA is a bifunctional chelator. p-NCS-Bz-DOTA-GA can be used as a versatile linker in targeted molecular imaging for both PET/SPECT and MRI applications .
    p-NCS-Bz-DOTA-GA
  • HY-164569
    NH2 DOTA-GA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NH2 DOTA-GA is a DOTA-based metal chelator that can be used to prepare radionuclide drug conjugates (RDCs) whose carboxylic acid groups can complex metal ions, for example, NH2 DOTA-GA complexes Gd(III) ions.
    NH2 DOTA-GA
  • HY-156038
    (S)-p-SCN-Bn-DOTA

    		Biochemical Assay Reagents Others
    (S)-p-SCN-Bn-DOTA is a bifunctional chelator (BFC), a macrocyclic DOTA derivative for tumor pretargeting. (S)-p-SCN-Bn-DOTA can be used for the conjugation of peptides and radionuclides, such as as a linker for In-111 labeled radioimmunoconjugates (RICs) for single photon emission tomography (SPECT) and in vitro biodistribution studies .
    (S)-p-SCN-Bn-DOTA
  • HY-153552A
    NH2-UAMC1110 TFA

    		FAP Cancer
    NH2-UAMC1110 TFA is an aminobutoxy derivative of the fibroblast activation protein (FAP) inhibitor UAMC1110 (HY-100684), and is a precursor compound for the synthesis of FAP inhibitor probes, not directly used in bioactivity experiments. For example, NH2-UAMC1110 TFA is involved in the synthesis of the radiotracer FAPI-QS, which exhibits high tumor selectivity and high dose effect, and has been used in tumor diagnosis. NH2-UAMC1110 TFA structurally incorporates an active amino group, allowing it to form covalent bonds with various molecules (such as DOTA, DATA5m, radionuclide chelators, etc.) to synthesize molecular imaging probes or targeted compounds with the ability to target FAP. NH2-UAMC1110 TFA specifically binds to the FAP active site, inhibiting its proline-selective serine protease activity (including dipeptidyl peptidase and endopeptidase activity), blocking FAP-mediated tissue remodeling-related processes. Its key activity is high targeting and high affinity, and its core function is to act as a targeting module coupled with bifunctional chelators (such as DOTA, DATA5m). NH2-UAMC1110 TFA can be applied to diagnostic imaging studies of tumors expressing FAP (such as colorectal cancer, pancreatic cancer, etc.), and also provides molecular tools for targeted research of FAP-related diseases with high FAP expression, such as fibrosis and arthritis .
    NH2-UAMC1110 TFA
  • HY-W539916
    Azido-mono-amide-DOTA

    		Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Others
    Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.
    Azido-mono-amide-DOTA
  • HY-157977
    DOTA-GA-maleimide

    		Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) MMP Cancer
    DOTA-GA-maleimide is a bifunctional chelator with protein conjugation and radiometal chelation capabilities. DOTA-GA-maleimide forms stable complexes with 111In and conjugates with proteins via maleimide chemistry. DOTA-GA-maleimide conjugates with LFn, enabling 111In radiolabeling of LFn through direct or pre-labeling strategies. Radiolabeled LFn is applicable to MMP activity imaging studies. DOTA-GA-maleimide is used in cancer research .
    DOTA-GA-maleimide
  • HY-153552
    NH2-UAMC1110

    		FAP Cancer
    NH2-UAMC1110 is an aminobutoxy derivative of the fibroblast activation protein (FAP) inhibitor UAMC1110 (HY-100684), and is a precursor compound for the synthesis of FAP inhibitor probes, not directly used in bioactivity experiments. For example, NH2-UAMC1110 is involved in the synthesis of the radiotracer FAPI-QS, which exhibits high tumor selectivity and high dose-response, and has been used for tumor diagnosis. NH2-UAMC1110 introduces an active amino group into its structure, enabling it to form covalent bonds with various molecules (such as DOTA, DATA5m, radionuclide chelators, etc.), thereby synthesizing molecular imaging probes or targeted compounds with the ability to target FAP. NH2-UAMC1110 specifically binds to the FAP active site, inhibiting its proline-selective serine protease activity (including dipeptidyl peptidase and endopeptidase activity), blocking FAP-mediated tissue remodeling processes. Its key activity is high targeting and high affinity, and its core function is to be coupled with bifunctional chelators (such as DOTA, DATA5m) as a targeting module. NH2-UAMC1110 can be applied to diagnostic imaging studies of tumors expressing FAP (such as colorectal cancer, pancreatic cancer, etc.), and also provides molecular tools for targeted research of FAP-related diseases with high FAP expression, such as fibrosis and arthritis .
    NH2-UAMC1110
  • HY-W749603
    Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester)

    		Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Cancer
    Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester) is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester) can be used for conjugation of peptides and radionuclides.
    Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester)
  • HY-100133A
    DOTA-ADIBO TFA

    		Integrin Cancer
    DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .
    DOTA-ADIBO TFA
  • HY-W755033
    NH2-PEG4-DOTA

    		Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Others
    NH2-PEG4-DOTA is a bifunctional DOTA chelator with one carboxyl group modified by NH2-PEG4, possessing both a metal-binding domain and a chemically reactive functional group. NH2-PEG4-DOTA can be used for time-resolved fluorescence assays .
    NH2-PEG4-DOTA
  • HY-W678394
    DOTA-Thiol

    		Biochemical Assay Reagents Others
    DOTA-Thiolis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-Thiol can be used for conjugation of peptides and radionuclides.
    DOTA-Thiol
  • HY-48876
    p-NH2-Bn-DOTA

    		Biochemical Assay Reagents Others
    p-NH2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA can be used for conjugation of peptides and radionuclides.
    p-NH2-Bn-DOTA
  • HY-164574
    BCN-DOTA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    BCN-DOTA is a cyclooctyne-linked DOTA chelator that can be radiolabeled with zirconium-89 as a radionuclide-labeled drug conjugate (RDC) to target specific biomolecules, cells, or tissues.
    BCN-DOTA
  • HY-P10729A
    DOTA-Bombesin (1-14) TFA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-Bombesin (1-14) TFA is composed of chelator DOTA and Bombesin (HY-P0195). DOTA-Bombesin (1-14) TFA is used for research of cancer through combination with radioactive elements. DOTA-Bombesin (1-14)TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    DOTA-Bombesin (1-14) TFA
  • HY-P6351
    c(avb6)-DOTA TFA

    		Integrin Cancer
    c(avb6)-DOTA TFA is a conjugate of the αvβ6 integrin selective peptide ring modified with DOTA chelator. The Lu(III) complex of c(avb6)-DOTA TFA has a comparable affinity for αvβ6 integrin (IC50=0.8 nM) and can be used as a tumor diagnostic .
    c(avb6)-DOTA TFA
  • HY-W782078
    Butyne-DOTA

    		Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Others
    Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.
    Butyne-DOTA
  • HY-W717779
    4-Aminobutyl-DOTA

    		Biochemical Assay Reagents Others
    4-Aminobutyl-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA can be used for conjugation of peptides and radionuclides.
    4-Aminobutyl-DOTA
  • HY-P10273A
    DOTA-Octreotide TFA

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Cancer
    DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    DOTA-Octreotide TFA
  • HY-158072
    DOTAM-NHS-ester

    		Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTAM-NHS-ester is a bifunctional chelator and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-NHS-ester combines the efficient metal chelating ability of DOTAM macrocyclic ligands with the bioconjugation function of NHS ester active groups, and can be widely used in the biomedical field for metal labeling, molecular imaging and drug delivery development .
    DOTAM-NHS-ester
  • HY-W451440
    Butyne-DOTA-tris(t-butyl ester)

    		Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Others
    Butyne-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.
    Butyne-DOTA-tris(t-butyl ester)
  • HY-164732
    Fmoc-Lys(DOTA)-OH

    		Amino Acid Derivatives Biochemical Assay Reagents Others
    Fmoc-Lys (DOTA)-OH is an Fmoc-protected Lysine derivative with metal-chelating properties, containing the macrocyclic chelator DOTA. Fmoc-Lys (DOTA)-OH undergoes metallation with Tb or Lu. Fmoc-Lys (DOTA)-OH utilizes metal coordination to protect the carboxyl groups of DOTA. Fmoc-Lys (DOTA)-OH can be used in solid-phase peptide synthesis research .
    Fmoc-Lys(DOTA)-OH
  • HY-164577
    BCN-DOTA-GA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    BCN-DOTA-GA is a cyclooctyne-linked DOTA chelator that can be labeled with radioactive zirconium-89 and used as a radionuclide-labeled drug conjugate (RDC) to target specific biomolecules, cells or tissues.
    BCN-DOTA-GA
  • HY-P10781
    PSMA-D5

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    PSMA-D5 has a binding affinity for PSMA with a Ki of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([68Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. PSMA-D5 ([68Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors . PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    PSMA-D5
  • HY-158118
    Lys(CO-C3-p-I-Ph)-OMe

    		DNA-PK Cancer
    Lys(CO-C3-p-I-Ph)-OMe is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules (such as Ac-PSMA-trillium). Lys(CO-C3-p-I-Ph)-OMe can increase the residence time of Ac-PSMA-trillium in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-OMe also reduces salivary gland absorption of Ac-PSMA-trillium, potentially extending its half-life. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
    Lys(CO-C3-p-I-Ph)-OMe
  • HY-W241345
    DOTA-bis(tert-butyl)ester

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-bis(tert-butyl)ester is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide conjugates (RDCs). DOTA-bis(tert-butyl)ester can be conjugated with different salts to form different metal chelators, such as (HY-B1244) hydrochloride to obtain DOTA-MN2. DOTA-MN2 can be reacted with [67]Ga-citrate to obtain radiolabeling. When (67)Ga-DOTA-MN2 is incubated in phosphate buffer solution or mouse plasma for 24 hours, it does not undergo significant decomposition. In the biodistribution experiment of NFSa tumor mice, it has high tumor uptake and rapid plasma clearance, and is a good material for SPECT and PET studies.
    DOTA-bis(tert-butyl)ester
  • HY-131673A
    (S)-p-SCN-Bn-TCMC hydrochloride

    		Biochemical Assay Reagents Others
    (S)-p-SCN-Bn-TCMC (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (S)-p-SCN-Bn-TCMC (hydrochloride) can be used for conjugation of peptides and radionuclides.
    (S)-p-SCN-Bn-TCMC hydrochloride
  • HY-158125
    PSMA binder-2

    		PSMA Cancer
    PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
    PSMA binder-2
  • HY-W088413
    DOTA-amide

    		Biochemical Assay Reagents Others
    DOTA-amideis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-amide can be used for conjugation of peptides and radionuclides.
    DOTA-amide
  • HY-128890A
    DOTA-NHS-ester hexafluorophosphate TFA

    		Biochemical Assay Reagents Others
    DOTA-NHS-ester (hexafluorophosphate TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-NHS-ester (hexafluorophosphate TFA) can be used for conjugation of peptides and radionuclides.
    DOTA-NHS-ester hexafluorophosphate TFA
  • HY-P10273
    DOTA-Octreotide

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Cancer
    DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is used for research of cancer, through combination with radioactive elements. DOTA-Octreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    DOTA-Octreotide
  • HY-P10729
    DOTA-Bombesin (1-14)

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-Bombesin (1-14) is composed of chelator DOTA and Bombesin (HY-P0195). DOTA-Bombesin (1-14) is used for research of cancer through combination with radioactive elements. DOTA-Bombesin (1-14) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    DOTA-Bombesin (1-14)
  • HY-W250844A
    DO3A trisodium

    		Biochemical Assay Reagents Others
    DO3A (trisodium)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO3A (trisodium) can be used for conjugation of peptides and radionuclides.
    DO3A trisodium
  • HY-P10743
    BQ7876

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    BQ7876
  • HY-W087187G
    DOTAGA-anhydride

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTAGA-anhydride (GMP) is DOTAGA-anhydride (HY-W087187) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .
    DOTAGA-anhydride
  • HY-W802013
    DOTA-4AMP

    		Biochemical Assay Reagents Others
    DOTA-4AMPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-4AMP can be used for conjugation of peptides and radionuclides.
    DOTA-4AMP
  • HY-W460274
    4-Aminobutyl-DOTA-tris(t-butyl ester)

    		Biochemical Assay Reagents Others
    4-Aminobutyl-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.
    4-Aminobutyl-DOTA-tris(t-butyl ester)
  • HY-W250929
    Maleimido-mono-amide-DOTA-tris(t-Bu ester)

    		Biochemical Assay Reagents Others
    Maleimido-mono-amide-DOTA-tris(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Maleimido-mono-amide-DOTA-tris(t-Bu ester) can be used for conjugation of peptides and radionuclides.
    Maleimido-mono-amide-DOTA-tris(t-Bu ester)
  • HY-W717760
    p-NH2-Bn-DOTA-tetra(t-Bu ester)

    		Biochemical Assay Reagents Others
    p-NH2-Bn-DOTA-tetra(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA-tetra(t-Bu ester) can be used for conjugation of peptides and radionuclides.
    p-NH2-Bn-DOTA-tetra(t-Bu ester)
  • HY-W782075
    p-NO2-Bn-DOTA

    		Biochemical Assay Reagents Others
    p-NO2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NO2-Bn-DOTA can be used for conjugation of peptides and radionuclides.
    p-NO2-Bn-DOTA
  • HY-W726767
    DO2A

    		Biochemical Assay Reagents Others
    DO2Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO2A can be used for conjugation of peptides and radionuclides.
    DO2A
  • HY-158077
    (R)-tetraMe-Tetraxetan

    (R)-tetraMe-DOTA

    		 Biochemical Assay Reagents Others
    (R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.
    (R)-tetraMe-Tetraxetan
  • HY-W088413A
    DOTA-amide dihydrate

    		Biochemical Assay Reagents Cancer
    DOTA-amide (dihydrate) is a Bifunctional Chelators (BFCs). DOTA-amide (dihydrate) binds to the Affibody molecule ZHER2:S1. Its complex binds specifically to HER2 and can be used to detect bone metastases, which are common in prostate cancer .
    DOTA-amide dihydrate
  • HY-W782081
    p-SCN-Bn-oxo-DO3A

    		Biochemical Assay Reagents Others
    p-SCN-Bn-oxo-DO3Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-SCN-Bn-oxo-DO3A can be used for conjugation of peptides and radionuclides.
    p-SCN-Bn-oxo-DO3A
  • HY-W782080
    p-NH2-Bn-oxo-DO3A

    		Biochemical Assay Reagents Others
    p-NH2-Bn-oxo-DO3Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-oxo-DO3A can be used for conjugation of peptides and radionuclides.
    p-NH2-Bn-oxo-DO3A
  • HY-186088
    DOTA-tris(t-Bu)ester-PEG3-C2-amine

    		Drug Intermediate Others
    DOTA-tris (t-Bu) ester-PEG3-C2-amine (Compound 9) is a conjugate of DOTA-based chelator and linker, bearing tris (t-Bu) ester and PEG3-C2-amine functional groups. DOTA-tris (t-Bu) ester-PEG3-C2-amine can be conjugated to payloads via bioorthogonal click chemistry for targeted delivery .
    DOTA-tris(t-Bu)ester-PEG3-C2-amine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: